Azienda Ospedaliero Universitaria Parma
Parma, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying treatments for advanced urothelial cancer, which is a type of cancer that affects the bladder and urinary system. The study will explore the effectiveness of a medication called durvalumab, also known by its code name MEDI4736, used in combination with standard chemotherapy treatments. Additionally, the trial will investigate the combination of durvalumab and another medication called tremelimumab with standard chemotherapy, compared to using standard chemotherapy alone.
The purpose of the study is to determine how well these combinations work in treating patients with this type of cancer. Participants in the study will receive treatments through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will compare the outcomes of patients receiving the different treatment combinations to see which is most effective in improving overall survival and controlling the disease.
Throughout the study, participants will be monitored to assess their response to the treatment and any side effects they may experience. The trial aims to provide valuable information on the potential benefits of combining durvalumab and tremelimumab with chemotherapy for patients with advanced urothelial cancer, helping to guide future treatment options for this condition.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
310 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Parma, Italy
Kecskemet, Hungary
Verona, Italy
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication used in this trial to help the immune system attack cancer cells. It is being tested in combination with standard chemotherapy to see if it can improve survival in patients with advanced urothelial cancer.
is another medication used in this trial, which also helps the immune system fight cancer. It is being tested alongside durvalumab and standard chemotherapy to determine if this combination can further enhance the treatment's effectiveness for patients with advanced urothelial cancer.
refers to the usual chemotherapy treatments given to patients with advanced urothelial cancer. In this trial, it is used alone or in combination with durvalumab and tremelimumab to compare the effectiveness of these different treatment approaches.
Durvalumab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating patients with unresectable locally advanced or metastatic urothelial cancer. It is primarily used in combination with standard chemotherapy to improve overall survival in patients with high PD-L1 expression. At the molecular level, durvalumab works by blocking the PD-L1 protein, which helps the immune system recognize and attack cancer cells. It is classified as an immune checkpoint inhibitor.
Tremelimumab is also administered intravenously and is being evaluated in combination with durvalumab and standard chemotherapy for the treatment of unresectable locally advanced or metastatic urothelial cancer. Its main therapeutic indication is to enhance the immune response against cancer cells. Tremelimumab functions by inhibiting the CTLA-4 protein, which boosts the immune system's ability to fight cancer. It is classified as an immune checkpoint inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.